# Shanghai STVC Group

> Shanghai STVC Group is a VC fund backing Manufacturing and Health Care. See 29 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 29
- Last investment: Apr 2026
- Lead investor: 24%
- Last updated: Aug 2026
- Website: http://www.shstvc.com.cn/

Shanghai STVC Group is a VC fund in Shanghai focused on Manufacturing and Health Care. Shanghai Science and Technology Venture Capital (Group) Co., Ltd. was formally inaugurated by Shanghai Science and Technology Investment Corporation and Shanghai Venture Capital Co., Ltd. through strategic restructuring. After the reorganization, the registered capital of Science and Technology Group was 1.69 billion yuan, and the directly managedfunds amounted to 12 billion yuan. Directly supervised by the Shanghai State-owned Assets Supervision and Administration Commission, the company is one of the largest state-owned venture capital institutions in Shanghai and even the whole country, and shoulders the mission of promoting the construction of Shanghai's globally influential science and technology innovation center.

## Contacts

5 contacts available for Shanghai STVC Group. Shizune tracks 1 team members at Shanghai STVC Group. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/shanghai-stvc-group?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Manufacturing | 8 | 28% |
| Health Care | 6 | 21% |
| Semiconductor | 6 | 21% |
| Medical | 5 | 17% |
| Biotechnology | 5 | 17% |

36 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 9 | 31% |
| Seed | 5 | 17% |
| Series A | 5 | 17% |
| Series C | 5 | 17% |
| Venture - Series Unknown | 2 | 7% |

8 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Weiguo Chen | General Manager, Executive Director | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| New Radiomedicine Technology | Chengdu New Radiomedicine Technology Co.,Ltd. is a Chinese medical isotopes provider. Our business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting.In April 2016, the company was founded bythree co-founders experienced in radionuclides research and development. Jihui Qian, former President of Nuclear Power Institute of China (NPIC), former Deputy Director-General of International Atomic Energy Agency (IAEA); Maoliang Li, former Director of Chengdu Isotopes Institute of NPIC; and Jiming Cai, former Vice President of Sichuan Institute of Atomic Energy.The company is located in Western Airport Development District, Shuangliu, Chengdu, with an area of 71 Are, registered capital of 32.83 million CNY, and total investment of 300 million CNY. The project is listed as "Annual Key Investment Projects of Sichuan Province and Chengdu City in 2017, 2018 and 2019". At present, the company has over 80 employees, with more than 60 R&D specialists, including 1 academician of Chinese Academy of Engineering, 2 experts of Thousand Talent Project, 2 academic and technical leaders from Sichuan province, 10 researchers (associate researchers), and more than 20 people with middle or senior titles. Among them, there are 6 PhDs and over 30 graduates. The proportion of R&D staff has reached 70%, making CNRT the most innovative technology enterprise in the radiopharmaceutical industry in China. | $145.4M | Series E | Apr 03, 2026 |  |
| Matrixtime Robotics | Matrixtime is an AI technology start-up. Based on deep learning, it is committed to the development of complex machine vision and industrial robot AI system products, empowering high-end manufacturing and providing scene-oriented industrial AI products. From high-end semiconductor manufacturing into complex machine vision inspection, Matrixtime hascovered scenarios including advanced semiconductor manufacturing, photovoltaic energy, automotive precision manufacturing, and unmanned ports. |  | Series B | Oct 20, 2025 |  |
| Contemporary Amperex Intelligence Technology | Contemporary Amperex Intelligence Technology (Shanghai) Limited (CAIT-SH) is focused on the development of the CATL Integrated Intelligent Chassis (CIIC) project, which incorporates a battery, electric drive, and Cell-to-Chassis (CTC) technology. | $280.7M |  | Oct 10, 2025 |  |
| Contemporary Amperex Intelligence Technology | Contemporary Amperex Intelligence Technology (Shanghai) Limited (CAIT-SH) is focused on the development of the CATL Integrated Intelligent Chassis (CIIC) project, which incorporates a battery, electric drive, and Cell-to-Chassis (CTC) technology. | $278.6M | Series A | Jul 28, 2025 |  |
| Zhixin Haozheng | Zhixin Haozheng is an inventor of regenerating islet technology. The company focuses on in vitro regeneration of human tissues and organs, with the major pipeline consisting of regenerative islets that can be implanted to cure diabetes. | $13.7M | Series A | May 06, 2025 |  |
| Noematrix | Noematrix is an embodied intelligence company that specializes in innovative general robotic intelligence solutions and services. |  | Seed | Apr 10, 2025 |  |
| Photoacoustic Pharmaceuticals | Photoacoustic Pharmaceuticals is an innovative developer of photosensitizers and related products. It is committed to advancing the development of dynamic photoacoustic therapy. |  | Series A | Nov 26, 2024 |  |
| Prospective Innovation Institute | The Prospective Innovation Institute is a technological achievement transformation service provider dedicated to the development of forward-thinking, disruptive, and unique technologies, as well as the organization of collaborative research on essential technologies. | $698.4K | Venture - Series Unknown | Aug 02, 2024 |  |
| Baoji Pharmaceutical | Baoji Pharmaceutical is a biopharma R&D manufacturer, a Sino-foreign joint biopharmaceutical enterprise integrating drug R&D and production. |  | Series C | Jul 19, 2024 |  |
| Huaxuan Sensing | Huaxuan Sensing is a sensor technology company that focuses on the development of resolver sensors for the new energy automobile industry. |  | Series B | Jun 05, 2024 |  |

10 of 29 investments shown.

## Co-investors
- [China Internet Investment Fund](https://shizune.co/investors/profile/china-internet-investment-fund) — VC Fund, 3 deals together
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 3 deals together
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund, 3 deals together
- [ZJ Innopark (Zhangjiang Hi-Tech Park)](https://shizune.co/investors/profile/zj-innopark) — VC Fund, 3 deals together
- [BAIC Capital](https://shizune.co/investors/profile/baic-capital) — VC Fund, 2 deals together
- [Boyu Capital](https://shizune.co/investors/profile/boyu-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Shanghai STVC Group invest in?

Shanghai STVC Group invests primarily in Manufacturing, Health Care and Semiconductor startups, most often at Series B and Seed stage. Most of the 29 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Shanghai STVC Group?

Public channels for Shanghai STVC Group include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Shanghai STVC Group?

The team at Shanghai STVC Group includes Weiguo Chen (General Manager, Executive Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co